International Journal of Clinical Case Reports, 2026, Vol.16, No.1, 1-10 http://medscipublisher.com/index.php/ijccr 10 Vellanki P., Ghosh S., Pathak A., Fusco M., Bloomquist E., Tang S., Singh H., Philip R., Pazdur R., and Beaver J.A., 2023, Regulatory implications of ctDNA in immuno-oncology for solid tumors, Journal for Immunotherapy of Cancer, 11: e005344. https://doi.org/10.1136/jitc-2022-005344 Wang Y.S., Shao W.J., Li H., Zhao P.Y., Tian L., Zhang L., Lan S., Zhong R., Zhang S., and Cheng Y., 2025, Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: a narrative review, Translational Lung Cancer Research, 14(3): 1007-1020. https://doi.org/10.21037/tlcr-24-942 Zheng J.C., Qin C.L., Wang Q.X., Tian D.B., and Chen Z.S., 2024, Circulating tumour DNA-based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis, eBioMedicine, 103: 105109. https://doi.org/10.1016/j.ebiom.2024.105109 Zhong R., Gao R., Fu W.H., Li C., Huo Z., Gao Y., Lu Y., Li F., Ge F., Tu H., You Z., He J., and Liang W., 2023, Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis, BMC Medicine, 21(1): 180. https://doi.org/10.1186/s12916-023-02849-z Zhu L.M., Xu R., Yang L.L., Shi W., Zhang Y., Liu J., Li X., Zhou J., and Bing P., 2023, Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review, Frontiers in Genetics, 14: 1172108. https://doi.org/10.3389/fgene.2023.1172108
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==